Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:

NCT ID: NCT03129139 Recruiting - Breast Cancer Clinical Trials

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā„¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Minnelide 101
Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelideā„¢Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors

NCT ID: NCT03099330 Recruiting - Advanced Cancer Clinical Trials

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Start date: July 19, 2017
Phase: Phase 1
Study type: Interventional

A study of TQ-B3139, inhibitor of ALK/C-Met tyrosine kinase, in patient with advanced cancer

NCT ID: NCT03030001 Recruiting - Advanced Cancer Clinical Trials

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Start date: February 15, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.

NCT ID: NCT03019276 Recruiting - Advanced Cancer Clinical Trials

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Start date: July 5, 2017
Phase: Phase 1
Study type: Interventional

To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a reasonable regimen for subsequent research.

NCT ID: NCT02996838 Recruiting - Advanced Cancer Clinical Trials

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Start date: May 11, 2017
Phase: Phase 1
Study type: Interventional

To study the pharmacokinetic characteristics of TQ-B3234 in the human body, recommend a reasonable regimen for subsequent research.

NCT ID: NCT02944864 Recruiting - Advanced Cancer Clinical Trials

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

Start date: August 13, 2017
Phase: Phase 1
Study type: Interventional

To study the pharmacokinetic characteristics of TQ-B3395 in the human body, recommend a reasonable regimen for subsequent research.

NCT ID: NCT02797795 Recruiting - Solid Tumors Clinical Trials

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

Start date: December 2016
Phase: Phase 1
Study type: Interventional

This study is a first-in-human, multicenter, open-label, nonrandomized, dose-escalation trial to be conducted in 2 sequential parts: - Part A (Dose Escalation) in subjects with advanced malignancies - Part B (Dose Confirmation) in subjects with tumor type(s) to be determined by results of Part A

NCT ID: NCT02779699 Recruiting - Advanced Cancer Clinical Trials

A Study of AL2846 on Tolerance and Pharmacokinetics

Start date: May 2016
Phase: Phase 1
Study type: Interventional

A study of AL2846,a C-met/Hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.

NCT ID: NCT02684318 Recruiting - Breast Cancer Clinical Trials

Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors

Start date: July 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors.

NCT ID: NCT02628067 Recruiting - Cervical Cancer Clinical Trials

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Start date: December 18, 2015
Phase: Phase 2
Study type: Interventional

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).